| Share

Kesem Health Selected for ANDHealth+ 2018, Australia’s only Mid-stage Digital Health Program

Melbourne, Australia, July. 23, 2018 - Kesem Health, a digital health company revolutionizing the diagnosis and management of urological diseases, announced today it succeeded in securing a place in Australian’s only mid-stage digital health program ANDHe

Kesem Health will receive up to $60,000 worth of specialist third party services and up to $150,000 of in kind support to enhance their ability to penetrate global markets and raise significant growth capital. No transfer of equity or intellectual property rights is required to participate in the ANDHealth+ program.

ANDHealth+ provides mid-stage digital health companies with support from proven experts to undertake a significant piece of work focused on securing the clinical and/or commercial evidence to enhance investment readiness and progress market entry strategy.

Kesem Health was selected together with four other companies into the 2018 cohort. A highly experienced industry selection panel chose from 42 high quality submissions from across Australia. The announcement was made by The Hon. Philip Dalidakis MP, Minister for Trade and Investment, Innovation and the Digital Economy, and Small Business.

"The ANDHealth+ program will support Kesem Health's continued progress in the commercialization of our novel technology. It also complements the FDA-clearance of the iUFlow™ solution and the company’s effort working towards a CE Mark for the utilization of the iUFlow™ solution in the EU market”, said Kesem Health's CEO, Gil Hidas.

Bronwyn Le Grice, Managing Director and CEO of ANDHealth said: “We are excited to be working with Kesem Health over the next months to bring their evidence-based technologies closer to market and investment readiness. ANDHealth fills a crucial gap in the Australian commercialisation landscape that would otherwise leave companies like Kesem Health without expert support and guidance to progress their technology.”

About Kesem Health and the iUFlow™ solution.

Kesem Health focuses on using the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia. Kesem is developing the world’s largest set of urinary flow data, utilizing the iUFlow - a low-cost, quick, and accurate method of measuring urinary output – information that is critical for the diagnosis and management of many urological conditions affecting more than 16% of the population (male, female and child), Irwin et al.

About ANDHealth

ANDHealth is a unique non- profit industry-led organisation focused on strengthening the Australian digital health ecosystem and de-risking innovations in digital health, with a focus on clinical evidence, commercialisation and investment readiness.

ANDHealth is comprised of a consortium of industry and government partners, with foundation members drawn from industry leaders nationally and internationally including Novartis Pharmaceuticals, RMIT University, Murdoch Children’s Research Institute, Planet Innovation, Curve Tomorrow, GP2U, AusBiotech, HealthXL, and HPM Executive and matching funding provided by Federal Government Industry Growth Centre MTPConnect.

For more information,
visit: www.KesemHealth.com
SOURCE Kesem Health   

Media Contact: assist@kesemHealth.com